Receptor tyrosine-protein kinase erbB-2, also known as HER2/Neu (human epidermal growth factor receptor 2), is a human epidermal growth factor receptor family member. Overexpression of HER2/Neu plays an essential role in developing and progressing specific subtypes of breast cancer. Approximately 15%-20% of all newly diagnosed breast cancers are HER2-positive, and HER2 testing identifies patients who benefit from HER2-targeted therapies, such as trastuzumab (Herceptin), lapatinib (Tykerb), pertuzumab (Perjeta), and T-DM1 (Kadcyla patients). There are two main ways to test HER2 status in cancer tissue: immunohistochemistry (IHC) which measures the amount of protein, and fluorescence in situ hybridization (FISH) which examines the number of HER2 gene copies.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue